Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Docking protein 1 (DOK1)
- Target
- DOK1
- Molecular classification
- Other (Adaptor/scaffold protein)
01
Overview
Docking protein 1 (DOK1) is a member of the DOK family of adaptor proteins, characterized by enzymatic inertness and the provision of a docking platform for signaling complexes. DOK1 is constitutively tyrosine phosphorylated in hematopoietic progenitors from patients with chronic myelogenous leukemia and serves as a critical substrate for the oncogenic p210(bcr/abl) fusion protein. Its domain structure includes a pleckstrin homology domain and multiple SH3 recognition motifs, facilitating interactions with other signaling proteins and modulation of downstream pathways such as insulin signaling and integrin activation. DOK1 acts as a scaffold that orchestrates cellular responses to external stimuli but is not a conventional receptor, enzyme, or therapeutic target in current clinical practice[1][2][3][6].
- Other names
- p62dokDownstream of tyrosine kinase 1pp62P62DOKDOK-1
02
Biological functions
Signal transduction (downstream of receptor tyrosine kinases)Negative regulation of insulin signalingFormation of multiprotein signaling complexesModulation of integrin activationMitogenic signaling
03
Disease associations
Cancer (chronic myelogenous leukemia, CML)Other (myopia, based on genetic association)
Beyond the preview
Go deeper on Docking protein 1 (DOK1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Docking protein 1 (DOK1).